Brind.

MIaMI was mentioned in connection with Naarden, Netherlands, while Menarini submitted an MAA for obicetrapib and partnered with NewAmsterdam.

3 reports, 2 independent Updated Sep 22
No new developments lately
Reports
3
Developments
1
Repetition
67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

MIaMI was mentioned in connection with Naarden, Netherlands, while Menarini submitted an MAA for obicetrapib and partnered with NewAmsterdam.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • themarketsdaily.com
  • GlobeNewswireNewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib -- Filings both for the obicetrapib monotherapy and obicetrapib plus e
1 more outlet ran the same wire story